Journal article icon

Journal article

Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials.

Abstract:

Capecitabine (Xeloda) and irinotecan (CPT-11, Camptosar) exhibit single-agent activity in colorectal cancer, have nonoverlapping major toxicities, and exhibit a synergistic effect in tumor xenograft models. European early-phase trials of the combination in patients with metastatic colorectal cancer indicate good response rates across doses tested and manageable toxicities, with available data supporting use of a regimen of oral capecitabine at 1,000 mg/m2 twice daily on days 1 to 14 plus IV i...

Expand abstract

Actions


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, RDM, Clinical Lab Sciences, Biomedical Research Centre
Role:
Author
Journal:
Oncology (Williston Park, N.Y.)
Volume:
16
Issue:
12 Suppl No 14
Pages:
12-15
Publication date:
2002-12-05
ISSN:
0890-9091
URN:
uuid:1d7b27e9-f4ed-42d6-af6d-f27b911a3bb3
Source identifiers:
246209
Local pid:
pubs:246209

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP